Real-World Situation of Eradication Regimens and Risk Factors for Helicobacter pylori Treatment in China: A Retrospective Single-Center Study
Clinical and Experimental Gastroenterology · 2024-07 · Volume 17 · 191-200
DOI: 10.2147/ceg.s466975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Gastroenterology, 2024-07. Verfasst von Jianping Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, People's Republic of China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background and Objectives: The success rate of Helicobacter pylori (H. pylori) eradication in China is declining. The aim of this study was to evaluate eradication outcomes in clinical practice and identifies factors contributing to treatment failure.
Methods
A retrospective review was conducted on patients treated for H. pylori infection with 14-day bismuth-containing quadruple therapy at a Beijing medical center from January 2020 to December 2023. We analyzed demographic and clinical data, eradication rates across regimens, and performed multivariate analysis to pinpoint predictors of failure.
Results
Out of 3340 participants, 2273 (68.1%) achieved eradication. Amoxicillin-based combinations (69.2%) outperformed other antibiotic regimens (58.9%, p < 0.001), with amoxicillin plus doxycycline reaching a 71.4% success rate. Esomeprazole-based regimens were more effective (73.6%) than other PPI regimens (65.2%, p = 0.001), notably, a rabeprazole, amoxicillin, doxycycline, and bismuth combination had an 80.0% success rate. Age, gender, and smoking and drinking were significant eradication failure predictors.
Conclusion
In real-world settings, 14-day amoxicillin and esomeprazole-based quadruple regimens have been demonstrated to be more effective than other regimens. Age, gender, and lifestyle habits are identified as independent risk factors for eradication failure. Registration: This study was registered in the Chinese Clinical Trial Registry on 08/01/2024 (clinical trial registration number: ChiCTR2400079647).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Oncology, Civil Aviation General Hospital, Beijing, People's Republic of China.
- Department of Medical Record, Civil Aviation General Hospital, Beijing, People's Republic of China.
- Department of Pharmacy, Civil Aviation General Hospital, Beijing, People's Republic of China.
- Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, People's Republic of China.
ORCID-Profile: Jianping Cheng, Yong Cai
Zitieren
APA
Cheng, J., Fan, C., Li, Z., Dong, Z., Zhao, X., Cai, Y., Ding, H., Dou, Y., & Zhang, X. (2024). Real-World Situation of Eradication Regimens and Risk Factors for Helicobacter pylori Treatment in China: A Retrospective Single-Center Study. Clinical and Experimental Gastroenterology, Volume 17, 191-200. https://doi.org/10.2147/ceg.s466975
Vancouver
Cheng J, Fan C, Li Z, Dong Z, Zhao X, Cai Y, et al. Real-World Situation of Eradication Regimens and Risk Factors for Helicobacter pylori Treatment in China: A Retrospective Single-Center Study. Clinical and Experimental Gastroenterology. 2024;Volume 17:191-200. doi:10.2147/ceg.s466975
BibTeX
@article{Cheng2024,
author = {Cheng, Jianping and Fan, Chanjuan and Li, Zhen and Dong, Zhaojing and Zhao, Xiaolin and Cai, Yong and Ding, Haiou and Dou, Yan and Zhang, Xiaomei},
title = {Real-World Situation of Eradication Regimens and Risk Factors for Helicobacter pylori Treatment in China: A Retrospective Single-Center Study},
journal = {Clinical and Experimental Gastroenterology},
year = {2024},
volume = {Volume 17},
pages = {191--200},
doi = {10.2147/ceg.s466975}
}
EUVIMED